• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6/25/25 6:05:20 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care
    Get the next $SVA alert in real time by email
    6-K 1 tm2518770d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2025

     

     

    Commission File Number: 001-32371

     

     

    SINOVAC BIOTECH LTD.

     

    No. 39 Shangdi Xi Rd, Haidian District

    Beijing 100085, People’s Republic of China

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F     x            Form 40-F     ¨

     

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      SINOVAC BIOTECH LTD.
         
      By:

    /s/ Chiang Li

      Name: Dr. Chiang Li
      Title: Chairman of the Board of Directors

     

    Date: June 24, 2025

     

     

     

    Exhibit Index

     

    Exhibit 99.1 Press Release - SINOVAC Board of Directors Files Investor Presentation
    Exhibit 99.2 Investor Presentation

     

     

    Get the next $SVA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SVA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place

      ISS states, "[T]he [current] board appears to be working to pay SVA shareholders their fair share of dividends, and to resume trading of the company's shares, which are the two most pressing issues currently facing SVA shareholders." SINOVAC's Board of Directors encourages shareholders to follow recommendations by ISS and Glass Lewis and VOTE the WHITE proxy card "AGAINST" the misguided proposals to remove the SINOVAC Board and appoint the Reconstituted Imposter Former Board Slate Special Meeting of SINOVAC shareholders to be held on July 8, 2025 To learn more, visit: VoteSinovac.com The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading

      7/3/25 7:34:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • United States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding Sinovac

      Court Found That 1Globe and Li Likely Violated Disclosure Obligations; Mandates Both File Updated Disclosures Within 5 Days of Order Decision Cites Prolonged Pattern of Corruption and Deception by 1Globe and Li Vivo Calls on All Shareholders to Support SAIF's Slate of Qualified Nominees, Reject 1Globe's Deception, and Stand Up for Transparent Corporate Governance Ahead of Special Meeting of Shareholders on July 8, 2025 Vivo Capital ("Vivo" or "we"), a leading global investment firm focused exclusively on healthcare and life sciences and a long-term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), today announced that the United States District Court of Ma

      7/2/25 10:55:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac

      Sinovac's Special Meeting of Shareholders is Just Days Away; Your Vote Matters No Matter How Many Shares You Own SAIF Partners Urges Shareholders to Vote the GOLD Proxy Card "FOR" its Director Candidates to End Years of Chaos, Restore Credibility and Unlock Long-Term Value for All Sinovac Shareholders SAIF Partners IV L.P., ("SAIF Partners", "we" or "us"), the largest single investor in Sinovac Biotech Ltd. ("Sinovac" or the "Company") which beneficially owns approximately 15% of the Company's outstanding common shares, today urged shareholders to immediately vote "FOR" the election of SAIF Partners' ten highly qualified director candidates to the Company's Board of Directors (the "Boar

      7/2/25 9:20:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care

    $SVA
    SEC Filings

    See more
    • SEC Form 6-K filed by Sinovac Biotech, Ltd.

      6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

      7/2/25 5:08:18 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SEC Form 6-K filed by Sinovac Biotech, Ltd.

      6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

      6/30/25 7:00:14 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SEC Form 6-K filed by Sinovac Biotech, Ltd.

      6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

      6/25/25 6:05:20 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care

    $SVA
    Financials

    Live finance-specific insights

    See more
    • United States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding Sinovac

      Court Found That 1Globe and Li Likely Violated Disclosure Obligations; Mandates Both File Updated Disclosures Within 5 Days of Order Decision Cites Prolonged Pattern of Corruption and Deception by 1Globe and Li Vivo Calls on All Shareholders to Support SAIF's Slate of Qualified Nominees, Reject 1Globe's Deception, and Stand Up for Transparent Corporate Governance Ahead of Special Meeting of Shareholders on July 8, 2025 Vivo Capital ("Vivo" or "we"), a leading global investment firm focused exclusively on healthcare and life sciences and a long-term shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), today announced that the United States District Court of Ma

      7/2/25 10:55:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac

      Sinovac's Special Meeting of Shareholders is Just Days Away; Your Vote Matters No Matter How Many Shares You Own SAIF Partners Urges Shareholders to Vote the GOLD Proxy Card "FOR" its Director Candidates to End Years of Chaos, Restore Credibility and Unlock Long-Term Value for All Sinovac Shareholders SAIF Partners IV L.P., ("SAIF Partners", "we" or "us"), the largest single investor in Sinovac Biotech Ltd. ("Sinovac" or the "Company") which beneficially owns approximately 15% of the Company's outstanding common shares, today urged shareholders to immediately vote "FOR" the election of SAIF Partners' ten highly qualified director candidates to the Company's Board of Directors (the "Boar

      7/2/25 9:20:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • Leading Independent Proxy Advisory Firm Glass Lewis Recommends SINOVAC Shareholders Vote to Keep the Current Board in Place

      Glass Lewis concludes, "[T]he current board has demonstrated credible progress in restoring governance stability and operational normalcy. [...] The Dissident Group's proposals, by contrast, rest on an inconsistent platform, rely on individuals linked to the governance failures of the past, and raise material questions about their ability to credibly resolve the challenges ahead." SINOVAC's Current Board of Directors encourages shareholders to follow Glass Lewis' Recommendation and VOTE the WHITE proxy card "AGAINST" the misguided proposals to remove the SINOVAC Board and appoint the Reconstituted Imposter Former Board Slate Special Meeting of SINOVAC shareholders to be held on July 8,

      7/2/25 1:03:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care

    $SVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

      SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

      9/12/24 4:03:46 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

      SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

      6/17/24 4:02:44 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Sinovac Biotech, Ltd. (Amendment)

      SC 13G/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

      3/20/24 7:33:23 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care

    $SVA
    Leadership Updates

    Live Leadership Updates

    See more
    • Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place

      ISS states, "[T]he [current] board appears to be working to pay SVA shareholders their fair share of dividends, and to resume trading of the company's shares, which are the two most pressing issues currently facing SVA shareholders." SINOVAC's Board of Directors encourages shareholders to follow recommendations by ISS and Glass Lewis and VOTE the WHITE proxy card "AGAINST" the misguided proposals to remove the SINOVAC Board and appoint the Reconstituted Imposter Former Board Slate Special Meeting of SINOVAC shareholders to be held on July 8, 2025 To learn more, visit: VoteSinovac.com The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading

      7/3/25 7:34:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong

      Hong Kong Court denies Advantech/Prime's petition for Interim Relief Clears another legal hurdle for distribution of the US$55.00 per common share special cash dividend declared by the current SINOVAC Board to be paid on or about July 7, 2025 The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has prevailed against the latest lawsuit filed by Advantech/Prime Success ("Advantech/Prime") in Hong Kong. This result follows Advantech/Prime's recently failed petition in New York last week, which was a repeated attempt by the purported PIPE Investors to block or delay a hearing f

      6/27/25 7:12:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SAIF Partners Files Definitive Proxy Materials in Connection with Sinovac Biotech 2025 Special Meeting of Shareholders; Nominates Ten Highly Qualified Director Candidates to the Board

      Sends Open Letter to Sinovac Shareholders Calling for a New Board to End Years of Chaos at Sinovac SAIF Nominees Will Work to Resolve Costly Legal Battles, Take Action to Resume Stock Trading after Six-Year Halt, and Facilitate Distribution of Cash That Rightfully Belongs to Shareholders Urges Sinovac Shareholders to VOTE the GOLD Proxy Card FOR the Election of SAIF's Director Nominees SAIF Partners IV L.P., ("SAIF Partners"), the largest single investor in Sinovac Biotech Ltd. ("Sinovac" or the "Company"), beneficially owning approximately 15% of the outstanding common shares, today announced that it has filed a definitive proxy statement for the election of ten director nominees to

      6/16/25 11:52:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care